Genetic testing IDs some at higher risk for colorectal cancer
The mother of a preschooler is taking advantage of some time to relax, read, and rest. The 36-year-old needs to save the strength she has for what's coming the next day: chemotherapy at Duly Health's cancer infusion center in Hinsdale.
'Chemo's miserable,' she said. 'It's really, really not fun.'
With her husband Patrick by her side, she's undergoing her eighth cycle of chemotherapy. Her hands and feet are covered in 'cold gloves and socks' to reduce two of chemo's most uncomfortable side-effects: cold sensitivity and neuropathy.
Her health ordeal started about one year ago when she came down with norovirus, an intense flu-like sickness that usually passes through the body within about 48-hours. But her abdominal pain lingered much longer.
'About a month after that, I was still having intermittent symptoms stomach pain,' Wozniak said. 'Diarrhea. Something was unsettled. But it seemed like I couldn't have a virus for that long.'
At first, doctors suspected that she had developed an ovarian cyst. 'I still was just feeling – in the morning – a cramping pain,' she said. 'Doubling over. I thought this was just not normal. So, I went to my primary care doctor, and she said this doesn't sound like it's only a cyst, let's send you for a CT. Sure enough, they saw some inflammation in my colon.'
Doctors ordered a colonoscopy and found she had two masses in her colon.
It was cancer.
'I realized right away that everything was going to be different, especially when I had another CT that showed some lesions on my liver, and again I was told, 'oh these could just be fluid filled cysts, nothing,'' she said. 'But it was this kind of intuition that this is not good, and sure enough those came back as cancerous, too.'
The cancer had advanced to stage four, meaning it had spread to other organs. 'Everything you hear about stage 4, you think this is not, this is going to be terminal for me, what am I going to do, I'm 35, I have a three-year-old, so it was pretty devastating and dark for those first few months,' she said.
According to the American Cancer Society, colorectal cancer is the leading cause of cancer death in men younger than 50, and the number two cause of cancer death among women under 50.
'There were a lot of moments where I just cried,' Wozniak said. 'I sat there crying and thinking, 'why is this happening to me?''
Wozniak is one of nearly 20,000 people younger than 50 who were diagnosed with colorectal cancer last year – a dramatic increase and a medical mystery.
'A lot of the media about it is in terms of, like, the environment, what people are eating, lifestyle choices and whatnot,' said Patrick Woulfe, Wozniak's husband. 'I think in Jessica's case that's not necessarily true because hers is due to a genetic condition.'
In Wozniak's case, the cause is clear. She has Lynch Syndrome, an inherited genetic condition associated with an increased risk for colon cancer.
'When I received the genetic test results that almost gave me some piece of mind because I thought, I was blaming myself a lot,' she said. 'Did I eat something that wasn't right? Did I do something to my body? What caused this? The genetic tests made me feel like, in a way, this was inevitable.'
Outside of genetic testing, colorectal cancers can be detected with colonoscopies.
In 2021 the U.S. Preventive Services Task Force lowered the recommended age of screenings from 50 to 45. It's still not young enough to catch many of the new cases.
'I would have rather had a million colonoscopies than deal with this,' Wozniak said. 'A colonoscopy is nothing compared to going through colon cancer.'
Wozniak is sifting through a pile of medical bills, and insurance information, wearing bracelets with the words 'fearless,' 'tough kid,' and her daughter's name. She said she wants to tell her story for her daughter and for everyone else who may have a chance to get screened before they get sick.
'I wish I would have known much sooner, so I could have been screened sooner and caught this sooner,' she said.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
5 days ago
- Yahoo
Betting Big on Cancer: 3 Oncology Stocks Set to Surge in 2025
An updated edition of the June 10, 2025, article. The global cancer treatment market is experiencing rapid growth, driven by rising cancer incidence, aging population and increasing demand for safer, more effective therapies. Per the American Cancer Society, in the United States alone, over 2 million new cancer cases and 618,000 related deaths are projected for 2025. Breakthroughs in immunotherapy, targeted treatments, and personalized cancer vaccines are reshaping the oncology landscape. These next-generation therapies offer greater precision and improved outcomes, supporting strong market expansion. Major pharma companies — including Novartis NVS, AstraZeneca AZN, Johnson & Johnson JNJ, Pfizer PFE, AbbVie ABBV, Bristol Myers Squibb and Eli Lilly LLY — are investing heavily in cutting-edge approaches like antibody-drug conjugates (ADCs) and immuno-oncology agents. Meanwhile, smaller biotechs are driving innovation, making them attractive acquisition targets for larger players seeking to enhance their oncology pipelines. As scientific progress accelerates, the oncology market is poised for robust, long-term growth — offering compelling opportunities for investors. These factors highlight the huge potential of cancer-focused companies. With our thematic screens, you can easily spot stocks tied to trends shaping the future of investing. If the cancer space appeals to you and you're looking to align your portfolio with this rising trend, now might be the time to consider stocks like J&J, Novartis and Allogene Therapeutics ALLO 3 Cancer Stocks in Focus J&J's Oncology segment comprises around 27% of its total revenues. Its oncology sales rose 22.3% on an operational basis in the second quarter of 2025 to $6.3 billion, driven by strong market growth and share gains of key products such as multiple myeloma treatment Darzalex and prostate cancer drug, Erleada. New cancer drugs, such as Carvykti, Tecvayli, Talvey and Rybrevant plus Lazcluze, contributed significantly to growth as they witnessed strong launches. On its second-quarter conference call, J&J stated that it expects its oncology sales to reach $50 billion by the end of the decade. J&J seems quite confident in the target, citing strong growth in its marketed cancer drugs and the potential of upcoming launches like TAR-200 in bladder cancer and the subcutaneous formulation of Rybrevant plus Lazcluze for advanced EGFR-mutated non-small cell lung cancer (NSCLC). TAR-200 is under priority review with the FDA for treating non-muscle invasive bladder cancer and is expected to be approved this year. The subcutaneous formulation of Rybrevant plus Lazcluze has been recommended for approval in the EU while it is under review in the United States. J&J's oncology pipeline has gained strong momentum in the last year and a half, with promising developments in colorectal and head and neck cancers. In this period, J&J had eight proof-of-concept readouts, which led the candidates to move to late-stage pivotal studies across the portfolio. J&J has a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Novartis has a diverse oncology portfolio, including targeted therapies and immunotherapies. The FDA's approval of Kisqali, its CDK4/6 inhibitor for the first-line treatment of postmenopausal women with HR+/HER2 advanced or metastatic breast cancer, significantly boosted the company's oncology portfolio, with the drug now being one of the top growth drivers for the company. In particular, Kisqali has shown robust uptake in the metastatic breast cancer setting. The recent approval of a broader label for Kisqali in the United States and the EU should further fuel its sales. Kisqali recorded sales of $1.1 billion in the second quarter of 2025, up 64% year over year. Other new oncology drugs like Pluvicto (PSMA-positive metastatic castration-resistant prostate cancer) and Scemblix (chronic myeloid leukemia) also put up a stellar performance, setting the momentum for the coming years as well. Novartis' oncology sales rose 20% in constant currency terms to $4.3 billion in the second quarter of 2025. In 2024, Novartis acquired Mariana Oncology and Germany-based MorphoSys AG, which strengthened its oncology pipeline. This Zacks Rank #2 company is also investing in research to develop treatments for both common and rare cancers, focusing on precision medicine strategies. Allogene Therapeutics is focused on developing allogeneic CAR T therapies for treating cancer, especially hematologic indications with high unmet needs. This Zacks Rank #2 company has multiple pipeline candidates in the clinical stage of development, including CAR T cell product candidates — cemacabtagene ansegedleucel (cema-cel or formerly ALLO-501A) and ALLO-316 for cancer indications. Lead candidate, cema-cel, is being developed as a frontline treatment for patients with large B-cell lymphoma (LBCL). In this regard, the company has initiated the pivotal phase II ALPHA3 study to evaluate cema-cel in patients with first-line LBCL. ALLO-316, the company's first CAR T candidate for solid tumors, is being evaluated in the TRAVERSE study in adults with advanced or metastatic renal cell carcinoma. Data from the study has shown that the therapy-induced early anti-tumor activity with deepening responses over time, especially in heavily pre-treated patients with high CD70 expression. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report AstraZeneca PLC (AZN) : Free Stock Analysis Report Novartis AG (NVS) : Free Stock Analysis Report Johnson & Johnson (JNJ) : Free Stock Analysis Report Pfizer Inc. (PFE) : Free Stock Analysis Report Eli Lilly and Company (LLY) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report Allogene Therapeutics, Inc. (ALLO) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
Yahoo
5 days ago
- Yahoo
SPF 30 vs SPF 50: What's the real difference in sun protection?
CHICAGO (WGN) — When it comes to protecting your skin from the sun's rays, not all sunscreens are created equal. According to the Skin Cancer Foundation, ultraviolet (UV) radiation from the sun is made up of two main types of rays that can damage your skin. UVB rays cause sunburn and UVA rays penetrate deeper and lead to skin aging, wrinkles and long-term damage. The SPF, or sun protection factor, mainly measures UVB protection. It indicates how much longer it would take for your skin to burn compared to if you weren't wearing any sunscreen at all. For example, with SPF 30, it would take you 30 times longer to burn than if you had no sunscreen on at all. The Skin Cancer Foundation says SPF 30 blocks about 97% of UVB rays while SPF 50 blocks about 98%. While the difference may seem small, the Skin Cancer Foundation says SPF 30 allows 50% more UV radiation to reach your skin than SPF 50, which can make a big difference if you're in the sun for a long period of time. But even when using a higher SPF, extra precautions should still be taken. The Skin Cancer Foundation stresses the importance of: Applying sunscreen 30 minutes before sun exposure Reapplying every two hours, or immediately after swimming or sweating Wearing protective clothing, hats and sunglasses For those who are at high risk of skin cancer, SPF 50 may not even be enough. In these cases, layering protection and seeking shade when possible becomes even more crucial. For any extended outdoor activity, the Skin Cancer Foundation recommends a water-resistant, broad-spectrum sunscreen with an SPF of 50 or higher. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.


Newsweek
18-07-2025
- Newsweek
Seven Questions for Miruna Sasu, Cancer Data and Research Guru
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Data is more important than ever before for health care organizations. In today's techy environment, hospitals and clinics can derive insights from vast patient records to deliver care more safely, effectively and efficiently. But patient data is often unstructured, and insights aren't always easy to glean—especially in specialties like oncology, where care records are particularly long and complex. That's where COTA Healthcare comes in. Its platform pulls data from electronic medical records at hospitals and clinics, cleans and adjudicates the clinical notes and then returns them to the health care organizations for cancer research and drug development purposes. That work has enormous potential, as the American Cancer Society estimates that more than 2 million new cancer cases will be diagnosed in 2025 alone. Despite the wide-ranging impacts, this mission is deeply personal for Miruna Sasu, the president and CEO of COTA Healthcare. Ahead of Newsweek's Women's Global Impact forum, Sasu told Newsweek how her work intertwines with her identity. Miruna Sasu is the president and CEO of COTA Healthcare and will be speaking at Newsweek's Women's Global Impact forum on August 5 in New York City. Miruna Sasu is the president and CEO of COTA Healthcare and will be speaking at Newsweek's Women's Global Impact forum on August 5 in New York City. Newsweek Illustration/Canva Newsweek: Walk me through your career trajectory. What sparked your interest in science / health care? Do you recall any formative experiences or mentors? Sasu: "The fight against cancer is personal for me. When I first moved to the U.S., my grandfather was diagnosed with Stage 4 lung cancer. Enrolling him in a clinical trial saved his life and gave us 35 more years with him. That time changed the course of my life. It allowed me to pursue my education and career, and it's a big part of why I do this work. The path to my current role has taken a few turns. I started in food safety with the federal government, then moved into life sciences at Bristol Myers Squibb, where I first worked with real-world data. I continued that work at Johnson & Johnson, focusing on making clinical trials more efficient. Eventually, I felt a strong pull to work entirely in cancer, which brought me to COTA. Along the way, I have been fortunate to have mentors who offered their time, insight and belief in me. Some of them recognized my leadership potential before I was ready to see it in myself. That kind of support shaped who I am and how I lead. It taught me to stay curious, to act with courage and to lead with empathy and purpose." What challenges did you face along the way, and what accomplishments are you most proud of? "There have been plenty of challenges. Change is hard, especially in health care. Most people care deeply about making a meaningful impact on patient outcomes, but org structures don't always make it easy. A lot of my work has focused on getting people aligned across departments and functions and on building trust so we can move forward together." What problems do you aim to solve in your current role? How do you measure progress toward your goals? "We are trying to solve a core problem in health care: how to use data to improve outcomes for patients. It's about making data not just available but actionable. We want to help pharma find the right patients for trials faster, support providers with better insights and ultimately help people get the care they need sooner." What are some recent projects or advancements that you're particularly excited about? "One of the most exciting developments at COTA is the launch of CAILIN, a new suite of AI-powered cancer data tools. For a long time, working with real-world data has required deep technical expertise and significant time to extract insights. CAILIN changes that by allowing users to ask complex research questions in plain language and receive answers within seconds. It also supports our medical abstractors by guiding them through the data curation process more efficiently, which helps improve both speed and quality. We are already seeing the impact of CAILIN across our work. Researchers, clinicians and life sciences teams can now access the insights they need without relying solely on data scientists. This kind of access accelerates decision-making and makes it easier for more people to work directly with high-quality oncology data. CAILIN is not a replacement for human expertise, but it is a powerful tool that helps us do more, faster. It is a meaningful step forward in cancer research, and I am incredibly proud of the team that made it possible." What are you most passionate about? Does your current role enable you to explore this passion? "I care deeply about using data to solve real-world problems. My passion lies in making health care more equitable, more effective and more humane. I'm also passionate about people. Building a healthy, inclusive team culture where people feel valued and motivated is something I work on just as intentionally as product or strategy. The two go hand in hand." Has being a woman shaped your leadership style and/or the way that you think about your work in the health care industry? "It has. Being a woman in leadership has taught me how to lead with both strength and empathy. I've had to work harder at times to prove myself, and that has made me more aware of how I show up and how I support others. I've learned to listen more, to trust my instincts and to lead with clarity. And I've made it a point to open doors for others wherever I can." Women make up 70% of the global health care workforce but hold just 25% of the industry's leadership positions. What do you make of this gender gap? How might we begin to close it? "It's a real gap, and it reflects long-standing structural issues, not a lack of qualified women. We need to be more intentional about creating pathways to leadership. That includes mentorship, sponsorship, fair hiring practices and making sure women have real opportunities to grow and lead. Representation also matters. When women see others leading at the highest levels, it expands what feels possible. I take that responsibility seriously and try to be the kind of leader I would have looked up to earlier in my own journey and to carve out paths for others to have an opportunity to do the same." Sasu will join Newsweek at this year's inaugural Women's Global Impact forum. The August 5 event, hosted at Newsweek's headquarters in New York City, will bring together some of the world's top female executives and connect them with rising stars across industries and job functions. For more information on the event, please visit the Women's Global Impact homepage.